Cite
HARVARD Citation
Planchard, D. et al. (n.d.). 1506TiPPhase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC. Annals of oncology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Planchard, D. et al. (n.d.). 1506TiPPhase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC. Annals of oncology. p. . [Online].